Blood biomarkers of mild traumatic brain injury: State of art

Sapin, Vincent; Gaulmin, Rémi; Aubin, Raphaël; Walrand, Stéphane; Coste, Aurélien; Abbot, Mathieu

doi:10.1016/j.neuchi.2021.01.001

Cited by 19 publications

(13 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To obtain quantitative insight into the distribution of clinically employed CSF biomarkers, we determined the ventricular versus lumbar levels of selected biomarkers with an ELISA-based approach. Of the employed biomarkers, only one (a biomarker of general neurodegeneration; S100B [38][39][40][41]) was detected in both the ELISA-based approach and the mass spectrometry-based analysis, and to verify the comparability between the approaches, we compared S100B between the methods (Fig. 3A).…”

Section: Clinical Biomarkers Distribute Differentially In the Csf Com...mentioning

confidence: 99%

Differential proteomic profile of lumbar and ventricular cerebrospinal fluid

Rostgaard

Olsen

Ottenheijm

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Pathological cerebral conditions may manifest in altered composition of the cerebrospinal fluid (CSF). Although diagnostic CSF analysis seeks to establish pathological disturbances in the brain proper, CSF is generally sampled from the lumbar compartment for reasons of technical ease and ethical considerations. We here aimed to compare the molecular composition of CSF obtained from the ventricular versus the lumbar CSF compartments to establish a relevance for employing lumbar CSF as a proxy for the CSF bathing the brain tissue. Methods: CSF was collected from 46 patients with idiopathic normal pressure hydrocephalus (iNPH) patients during their diagnostic workup (lumbar samples) and in connection with their subsequent CSF diversion shunt surgery (ventricular samples). The mass-spectrometry-based proteomic profile was determined in these samples and in addition, selected biomarkers were quantified with ELISA (S100B, neurofilament light (NfL), amyloid-β (Aβ40, Aβ42), and total tau (T-tau) and phosphorylated tau (P-tau) forms). The latter analysis was extended to include paired porcine samples obtained from the lumbar compartment and the cerebromedullar cistern closely related to the ventricles. Results: In total 1,231 proteins were detected in the human CSF. Of these, 216 distributed equally in the two CSF compartments, whereas 22 were preferentially (or solely) present in the ventricular CSF and four in the lumbar CSF. The selected biomarkers of neurodegeneration and Alzheimer’s disease displayed differential distribution, some with higher (S100B, T-tau, and P-tau) and some with lower (NfL, Aβ40, Aβ42) levels in the ventricular compartment. In the porcine samples, all biomarkers were most abundant in the lumbar CSF. Conclusions: For a range of CSF proteins and biomarkers, one can reliably employ lumbar CSF as a proxy for ventricular CSF. However, the overall proteomic profile differs between these compartments, and so does the distribution of clinically employed biomarkers. It is therefore important to verify the compartmental preference of the proteins or biomarkers of interest prior to extrapolating from lumbar CSF to that of the ventricular fluid bordering the brain.

show abstract

Section: Clinical Biomarkers Distribute Differentially In the Csf Com...mentioning

confidence: 99%

Differential proteomic profile of lumbar and ventricular cerebrospinal fluid

Rostgaard

Olsen

Ottenheijm

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Although well recognised and validated, acute TBI biomarkers may overlap with other disease and injury processes, such as extracranial plasma or serum, proteins released from damaged cells, polytraumatic organ and muscle injury 66,192 , lung tumours 193 , and subclinical ND conditions 74,109 . Despite this however, in 2007 the Scandinavian healthcare system introduced S100B as the first brain biomarker to be used within clinical practice guidelines to predict negative CT scans, aiming to reduce the number of unnecessary scans on patients without significant TBI 82,187,194 . Recognised biomarkers measured in the acute phase after TBI include, S100B, glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), Ubiquitin C-terminal hydrolase-L1 (UCHL1), total tau (t-tau) protein and αIIspectrin breakdown products 40,173 , which align with standard TBI diagnostics, for example measuring raised concentrations of GFAP, S100B, UCHL1 NSE and t-tau in blood when abnormalities are present in CT scans 174 .…”

Section: 1mentioning

confidence: 99%

“…Many TBI biomarkers are assayed in accessible biofluids [40] , [66] , [80] , [167] , [173] , [175] , [183] , [185] – [187] . Pineda et al , stated that ‘good’ biomarkers should be in easily accessible biofluids, with low background levels in healthy control groups, have high sensitivity and specificity to all injury severities and be released in a “time-locked sequence” after the injury [40] , [188] , [189] .…”

Section: Chemical Responses To Tbimentioning

confidence: 99%

Section: Chemical Responses To Tbimentioning

confidence: 99%

See 1 more Smart Citation

Review: Emerging Eye-Based Diagnostic Technologies for Traumatic Brain Injury

Harris

Rickard

Butt

et al. 2023

IEEE Rev. Biomed. Eng.

View full text Add to dashboard Cite

The study of ocular manifestations of neurodegenerative disorders, Oculomics, is a growing field of investigation for early diagnostics, enabling structural and chemical biomarkers to be monitored overtime to predict prognosis. Traumatic brain injury (TBI) triggers a cascade of events harmful to the brain, which can lead to neurodegeneration. TBI, termed the "silent epidemic" is becoming a leading cause of death and disability worldwide. There is currently no effective diagnostic tool for TBI, and yet, earlyintervention is known to considerably shorten hospital stays, improve outcomes, fasten neurological recovery and lower mortality rates, highlighting the unmet need for techniques capable of rapid and accurate point-of-care diagnostics, implemented in the earliest stages. This review focuses on the latest advances in the main neuropathophysiological responses and the achievements and shortfalls of TBI diagnostic methods. Validated and emerging TBI-indicative biomarkers are outlined and linked to ocular neuro-disorders. Methods detecting structural and chemical ocular responses to TBI are categorised along with prospective chemical and physical sensing techniques. Particular attention is drawn to the potential of Raman spectroscopy as a non-invasive sensing of neurological molecular signatures in the ocular projections of the brain, laying the platform for the first tangible path towards alternative point-of-care diagnostic technologies for TBI.

show abstract

“…This criteria makes an accurate diagnosis challenging due to symptom ambiguity, the subjective nature of symptoms reporting and the high prevalence of concussion-like symptoms in the general population 4. Objective measures of mTBI diagnosis have been proposed including advanced imaging and blood-based biomarker assays 5. However, these measures can be invasive, expensive and limited to specialty hospital settings.…”

Section: Introductionmentioning

confidence: 99%

Non-invasive fluid biomarkers in the diagnosis of mild traumatic brain injury (mTBI): a systematic review

Feinberg

Mayes

Portman

et al. 2023

J Neurol Neurosurg Psychiatry

View full text Add to dashboard Cite

BackgroundDespite approximately 55.9 million annual mild traumatic brain injuries (mTBIs) worldwide, the accurate diagnosis of mTBI continues to challenge clinicians due to symptom ambiguity, reliance on subjective report and presentation variability. Non-invasive fluid biomarkers of mTBI offer a biological measure to diagnose and monitor mTBI without the need for blood draws or neuroimaging. The objective of this study is to systematically review the utility of such biomarkers to diagnose mTBI and predict disease progression.MethodsA systematic review performed in PubMed, Scopus, Cochrane and Web of Science followed by a manual search of references without a specified timeframe. Search strings were generated and run (27 June 2022) by a research librarian. Studies were included if they: (1) included human mTBI subjects, (2) assessed utility of a non-invasive biomarker and (3) published in English. Exclusion criteria were (1) non-mTBI subjects, (2) mTBI not assessed separately from moderate/severe TBI, (3) required intracranial haemorrhage or (4) solely assesses genetic susceptibility to mTBI.ResultsA total of 29 studies from 27 subject populations (1268 mTBI subjects) passed the inclusion and exclusion criteria. Twelve biomarkers were studied. Salivary RNAs, including microRNA, were assessed in 11 studies. Cortisol and melatonin were assessed in four and three studies, respectively. Eight salivary and two urinary biomarkers contained diagnostic or disease monitoring capability.DiscussionThis systematic review identified several salivary and urinary biomarkers that demonstrate the potential to be used as a diagnostic, prognostic and monitoring tool for mTBI. Further research should examine miRNA-based models for diagnostic and predictive utility in patients with mTBI.PROSPERO registration numberCRD42022329293.

show abstract

Blood biomarkers of mild traumatic brain injury: State of art

Cited by 19 publications

References 76 publications

Differential proteomic profile of lumbar and ventricular cerebrospinal fluid

Differential proteomic profile of lumbar and ventricular cerebrospinal fluid

Review: Emerging Eye-Based Diagnostic Technologies for Traumatic Brain Injury

Non-invasive fluid biomarkers in the diagnosis of mild traumatic brain injury (mTBI): a systematic review

Contact Info

Product

Resources

About